Literature DB >> 22975773

[CD20-positive peripheral T-cell lymphoma, not otherwise specified].

Honoka Arai1, Kazuhiro Maki, Jiro Tadokoro, Tomoyuki Handa, Yuko Nakamura, Shigeharu Tsurumi, Ko Sasaki, Kinuko Mitani.   

Abstract

We report a 69-year-old male with CD3-positive peripheral T-cell lymphoma, not otherwise specified (PTCL-nos). Interestingly, tumor cells slightly expressed CD20 as well. Southern analyses of the tumor cells showed rearrangement for only the T cell receptor gene but not the immunoglobulin genes. This patient achieved partial remission with a treatment regimen of THP-COP excluding prednisolone, but died of pneumonia. Although CD20-positive PTCL is rare, a review of the reported cases suggests that CD20-positive PTCL has a poor prognosis and that bone marrow infiltration of tumor cells results in a poorer prognosis in CD20-positive PTCL than in usual PTCL. By accumulating cases of this rare entity of lymphoma, we need to clarify the biological nature of the tumor cells and usefulness of rituximab combined with standard chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22975773

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  1 in total

Review 1.  CD20-positive primary gastric T-cell lymphoma poorly responding to initial treatment with rituximab plus CHOP, and a literature review.

Authors:  Yasutaka Kakinoki; Junichi Hashiguchi; Takashi Ishio; Koji Chiba; Daisuke Niino; Koichi Ohshima
Journal:  Int J Hematol       Date:  2015-08-07       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.